N M van Schoor1, H Yu, J Bobula, P Lips. 1. EMGO Institute, VU University Medical Center, Van der Boechorststraat 7, 1081 BT, Amsterdam, The Netherlands. nm.vanschoor@vumc.nl
Abstract
SUMMARY: Not much is known about cross-geographic region differences in quality of life (QoL) in women with and without prevalent vertebral fractures (VFX). QoL differed between continents, countries, and ethnicities. The observed differences in QoL mostly appeared larger than the difference in QoL between women with or without mild to moderate VFX. INTRODUCTION:Quality of life (QoL) is an increasingly important outcome measure in randomized controlled trials and cost-utility studies. However, not much is known about cross-geographic region differences in QoL. The objective of this study was to describe the cross-geographic region differences in QoL in women with and without mild to moderate prevalent vertebral fractures (VFX). METHODS: The study was performed using baseline data of the bazedoxifene study. The study was carried out in 25 countries in six continents (n = 7117). QoL was assessed using the index and Visual Analogue Scale (VAS) scores of the EQ-5D, Qualeffo-41, and Women's Health Questionnaire (WHQ). VFX were assessed using semi-quantitative and quantitative morphometric methods. RESULTS: In general, all four instruments followed more or less the same pattern. In most analyses, the reported QoL was lowest in Asia and Europe and highest in North America and Oceania. To examine the influence of ethnicity, North and South America were stratified on race. In both continents, a lower QoL was observed in Hispanic people. CONCLUSIONS:QoL differed between continents, countries, and ethnicities. The observed differences in QoL appeared larger between most continents and countries than the difference in QoL between women with or without mild to moderate VFX.
RCT Entities:
SUMMARY: Not much is known about cross-geographic region differences in quality of life (QoL) in women with and without prevalent vertebral fractures (VFX). QoL differed between continents, countries, and ethnicities. The observed differences in QoL mostly appeared larger than the difference in QoL between women with or without mild to moderate VFX. INTRODUCTION: Quality of life (QoL) is an increasingly important outcome measure in randomized controlled trials and cost-utility studies. However, not much is known about cross-geographic region differences in QoL. The objective of this study was to describe the cross-geographic region differences in QoL in women with and without mild to moderate prevalent vertebral fractures (VFX). METHODS: The study was performed using baseline data of the bazedoxifene study. The study was carried out in 25 countries in six continents (n = 7117). QoL was assessed using the index and Visual Analogue Scale (VAS) scores of the EQ-5D, Qualeffo-41, and Women's Health Questionnaire (WHQ). VFX were assessed using semi-quantitative and quantitative morphometric methods. RESULTS: In general, all four instruments followed more or less the same pattern. In most analyses, the reported QoL was lowest in Asia and Europe and highest in North America and Oceania. To examine the influence of ethnicity, North and South America were stratified on race. In both continents, a lower QoL was observed in Hispanic people. CONCLUSIONS: QoL differed between continents, countries, and ethnicities. The observed differences in QoL appeared larger between most continents and countries than the difference in QoL between women with or without mild to moderate VFX.
Authors: J D Adachi; G Loannidis; C Berger; L Joseph; A Papaioannou; L Pickard; E A Papadimitropoulos; W Hopman; S Poliquin; J C Prior; D A Hanley; W P Olszynski; T Anastassiades; J P Brown; T Murray; S A Jackson; A Tenenhouse Journal: Osteoporos Int Date: 2001 Impact factor: 4.507
Authors: P Lips; C Cooper; D Agnusdei; F Caulin; P Egger; O Johnell; J A Kanis; S Kellingray; A Leplege; U A Liberman; E McCloskey; H Minne; J Reeve; J Y Reginster; M Scholz; C Todd; M C de Vernejoul; I Wiklund Journal: Osteoporos Int Date: 1999 Impact factor: 4.507
Authors: Jordi Alonso; Montserrat Ferrer; Barbara Gandek; John E Ware; Neil K Aaronson; Paola Mosconi; Niels K Rasmussen; Monika Bullinger; Shunichi Fukuhara; Stein Kaasa; Alain Leplège Journal: Qual Life Res Date: 2004-03 Impact factor: 4.147
Authors: W Cockerill; M Lunt; A J Silman; C Cooper; P Lips; A K Bhalla; J B Cannata; R Eastell; D Felsenberg; C Gennari; O Johnell; J A Kanis; C Kiss; P Masaryk; M Naves; G Poor; H Raspe; D M Reid; J Reeve; J Stepan; C Todd; A D Woolf; T W O'Neill Journal: Osteoporos Int Date: 2003-11-13 Impact factor: 4.507
Authors: Ivana Tadic; Nada Vujasinovic Stupar; Ljiljana Tasic; Dejan Stevanovic; Aleksandar Dimic; Bojana Stamenkovic; Sonja Stojanovic; Sasa Milenkovic Journal: Health Qual Life Outcomes Date: 2012-06-18 Impact factor: 3.186
Authors: José Sanfélix-Genovés; Isabel Hurtado; Gabriel Sanfélix-Gimeno; Begoña Reig-Molla; Salvador Peiró Journal: Health Qual Life Outcomes Date: 2011-04-06 Impact factor: 3.186